Alzheimer's disease research has made significant strides in recent years, reshaping our understanding of the brain's immune system and its role in neurodegenerative diseases.Leading this transformative effort is neuroscientist Beth Stevens, whose groundbreaking studies focus on microglial cells—the brain's defenders against illness and injury.
Research on TIM-3 and Alzheimer's treatment is charting new territory in the quest for effective therapies against this debilitating disease.TIM-3, an immune checkpoint molecule, has emerged as a significant factor influencing how the brain's immune cells, known as microglia, combat the accumulation of amyloid plaques associated with Alzheimer's.